Table 2.
Change from baseline in pain intensity during RCT double-blind phase
| Treatment (n) | Mean score (SD) | Change from baseline (SD) | Change versus placeboa | P-value |
|---|---|---|---|---|
| Week 2 | ||||
| Methylnaltrexone 12 mg qd (n=132) | 6.2 (1.9) | 0.0 (1.7) | 0.1 | 0.69 |
| Methylnaltrexone 12 mg qod (n=132) | 6.1 (1.9) | −0.1 (1.5) | 0.0 | 0.97 |
| Placebo (n=153) | 6.2 (2.0) | −0.1 (1.4) | ||
| Week 4 | ||||
| Methylnaltrexone 12 mg qd (n=122) | 6.1 (1.9) | −0.2 (1.6) | −0.1 | 0.64 |
| Methylnaltrexone 12 mg qod (n=120) | 5.9 (1.7) | −0.3 (1.5) | −0.3 | 0.15 |
| Placebo (n=143) | 6.3 (2.0) | −0.1 (1.8) | ||
Note:
a
Difference in adjusted change from baseline versus placebo.
Abbreviations: qd, once daily; qod, every other day; RCT, randomized controlled trial; SD, standard deviation.